Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of IL-YANG Quadrivalent Flu Vaccine in Healthy Korean Adults
NCT02480998Phase 2Completed
- Sponsor
- Il-Yang Pharmaceutical
- Start
- Feb 2015
- Primary completion
- Apr 2015
01
Overview
Phase 2, randomised, double-blind trial in influenza (2 arms), sponsored by Il-Yang Pharmaceutical. Primary endpoints: Seroconversion Rate at 28 days and Seroprotection Rate at 28 days. Started Feb 2015; status: completed.
02
Conditions
influenza
Beyond the preview
Go deeper on NCT02480998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02480998.